Microsoft word - r0497319.rtf

SIGMA-ALDRICH
sigma-aldrich.com
Material Safety Data Sheet

1. PRODUCT AND COMPANY IDENTIFICATION
Sigma-Aldrich Manufacturer : Sigma-Aldrich Corporation 3050 Spruce Street both supplier and manufacturer) Preparation Information Product Safety - Americas Region 1-800-521-8956
2. HAZARDS IDENTIFICATION
Emergency Overview
OSHA Hazards
Target Organ Effect, Toxic by ingestion, Irritant
Target Organs
GHS Classification
Acute toxicity, Oral (Category 3)
Skin irritation (Category 2)
Eye irritation (Category 2A)
Specific target organ toxicity - single exposure (Category 3)
GHS Label elements, including precautionary statements
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. IF SWALLOWED: Immediately call a POISON CENTER or doctor/ physician. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. HMIS Classification
Health hazard:
Sigma - A2093
Chronic Health Hazard:
Flammability:
Physical hazards:
NFPA Rating
Health hazard:
Reactivity Hazard:
Potential Health Effects
Inhalation
May be harmful if inhaled. Causes respiratory tract irritation. May be harmful if absorbed through skin. Causes skin irritation. Ingestion

3. COMPOSITION/INFORMATION ON INGREDIENTS
ASA O-Acetylsalicylic acid 2-Acetoxybenzoic acid Acetylsalicylic acid Aspirin O-Acetylsalicylic acid
50-78-2 200-064-1

4. FIRST AID MEASURES
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

5. FIRE-FIGHTING MEASURES
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for fire-fighters
Wear self contained breathing apparatus for fire fighting if necessary.
Hazardous combustion products
Hazardous decomposition products formed under fire conditions. - Carbon oxides

6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Wear respiratory protection. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas. Avoid breathing dust.
Sigma - A2093
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for
disposal.

7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Components with workplace control parameters
USA. OSHA - TABLE Z-1 Limits for Air Contaminants - Personal protective equipment
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N99
(US) or type P2 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole
means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved
under appropriate government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in
accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate
government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
Complete suit protecting against chemicals, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Hygiene measures
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Safety data
Sigma - A2093
Melting point/range: 134 - 136 °C (273 - 277 °F) - lit.
10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents, Strong acids, Strong bases
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides
Other decomposition products - no data available
Thermal decomposition
140 °C

11. TOXICOLOGICAL INFORMATION
Acute toxicity
Oral LD50
LD50 Oral - rat - 200 mg/kg
Inhalation LC50
Dermal LD50
no data available
Other information on acute toxicity
LD50 Intraperitoneal - rat - 340 mg/kg
LD50 Intraperitoneal - mouse - 167 mg/kg Skin corrosion/irritation
Sigma - A2093
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity

no data available
Carcinogenicity
No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH. No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. Reproductive toxicity
Overexposure may cause reproductive disorder(s) based on tests with laboratory animals. Teratogenicity
Specific target organ toxicity - single exposure (Globally Harmonized System)
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure (Globally Harmonized System)
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. Causes respiratory tract irritation. Ingestion
May be harmful if absorbed through skin. Causes skin irritation. Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects
no data available
Additional Information
RTECS: VO0700000

12. ECOLOGICAL INFORMATION
Toxicity
LC50 - Leuciscus idus (Golden orfe) - > 1,000 mg/l - 48 h LC50 - Bacteria - > 10,000 mg/l - 48 h Sigma - A2093
Persistence and degradability
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects

13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a
chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods

15. REGULATORY INFORMATION
OSHA Hazards
Target Organ Effect, Toxic by ingestion, Irritant
DSL Status
All components of this product are on the Canadian DSL list.
SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold
(De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
Acute Health Hazard, Chronic Health Hazard
Massachusetts Right To Know Components
Pennsylvania Right To Know Components
New Jersey Right To Know Components
Sigma - A2093
California Prop. 65 Components
WARNING! This product contains a chemical known to the State of California to cause birth defects or other reproductive harm.
16. OTHER INFORMATION
Further information
Copyright 2011 Sigma-Aldrich Co. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Co., shall not be held liable for any damage resulting from handling or from contact with the
above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.
Sigma - A2093

Source: http://dept.harpercollege.edu/chemistry/msds/Aspirin%20powder%20SigmaAldrich.pdf

Microsoft word - 09-06-30_fjord.doc

Santhera Pharmaceuticals Holding AG Santhera’s FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia in Parkinson’s Disease Liestal, Switzerland, June 30, 2009 – Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today positive data from its Phase I

Microsoft word - 01-camp-prog.doc

Experiment #1: Cyclic AMP and progesterone accumulation in MA-10 cells Introduction. Cells will be incubated with buffer only or with a maximally effective concentration ofhCG. Cyclic AMP and progesterone (the main steroid product of MA-10 cells) will bemeasured as endpoints at the end of the incubation. The incubation for the cAMPassay will be done in the presence of a phosphodiesterase in

Copyright © 2010-2014 Drug Shortages pdf